Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 21 Brain Neoplasms 9 Neoplasms 7 Glioma 6 Astrocytoma 4 Recurrence 3 Solid Tumor 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia-Lymphoma, Adult T-Cell 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Camurati-Engelmann Syndrome 1 Breast Neoplasms 1 Bone Neoplasms 1

Interventions

Injections 12 pembrolizumab 11 Nivolumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Cisplatin 6 Capecitabine 6 Gemcitabine 5 toripalimab 4 tislelizumab 4 atezolizumab 4 Ipilimumab 4 Bevacizumab 4 Rifampin 3 Oxaliplatin 3 Itraconazole 3 Carboplatin 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 sintilimab 2 pertuzumab 2 ontuxizumab 2 navoximod 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × Lomustine × Clear all

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡